Cargando…
The future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease in various GOLD groups: a focus on the GOLD 2017 and GOLD 2023 reports
BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 report revised the combined assessment, merged the C and D groups into the E group, and revised the initial inhalation therapy recommendation. OBJECTIVES: This study aimed to analyze the future exacerbation and mortal...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685753/ https://www.ncbi.nlm.nih.gov/pubmed/38018090 http://dx.doi.org/10.1177/17534666231213715 |
_version_ | 1785151698991316992 |
---|---|
author | Song, Qing Cheng, Wei Liu, Cong Li, Xueshan Lin, Ling Peng, Yating Zeng, Yuqin Yi, Rong Liu, Yi Li, Xin Chen, Yan Cai, Shan Chen, Ping |
author_facet | Song, Qing Cheng, Wei Liu, Cong Li, Xueshan Lin, Ling Peng, Yating Zeng, Yuqin Yi, Rong Liu, Yi Li, Xin Chen, Yan Cai, Shan Chen, Ping |
author_sort | Song, Qing |
collection | PubMed |
description | BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 report revised the combined assessment, merged the C and D groups into the E group, and revised the initial inhalation therapy recommendation. OBJECTIVES: This study aimed to analyze the future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease (COPD) in various groups based on the GOLD 2017 and GOLD 2023 reports. DESIGN: This is a multicenter and retrospective study. METHODS: Stable COPD patients from the database setup by 12 hospitals were enrolled. The patients were divided into Groups A, B, C, D, and E according to the GOLD 2017 and GOLD 2023 reports. Then, the patients were classified into long-acting muscarinic antagonist (LAMA), long-acting β2-agonist (LABA) + inhaled corticosteroid (ICS), LABA + LAMA, and LABA + LAMA + ICS subgroups. Data on exacerbation and death during 1 year of follow-up were collected. RESULTS: A total of 4623 patients were classified into Group A (15.0%), Group B (37.8%), Group C (7.3%), Group D (39.9%), and Group E (47.2%). The exacerbation, frequent exacerbation, and mortality showed no differences between different inhalation therapies in Groups A and C. Patients treated with LABA + LAMA or LABA + LAMA + ICS had a lower incidence of exacerbation and frequent exacerbation than patients treated with LAMA or LABA + ICS in Groups B, D, and E. The exacerbation, frequent exacerbation, and mortality showed no differences between different inhalation therapies after combining Groups A with C. CONCLUSION: Patients in Group A should be recommended to undergo mono-LAMA, while patients in Groups B and E should be recommended treatment with LABA + LAMA, which is consistent with the GOLD 2023 report. However, it is worth considering merging Groups A and C into a single group and recommending mono-LAMA as the initial inhalation therapy. |
format | Online Article Text |
id | pubmed-10685753 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-106857532023-11-30 The future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease in various GOLD groups: a focus on the GOLD 2017 and GOLD 2023 reports Song, Qing Cheng, Wei Liu, Cong Li, Xueshan Lin, Ling Peng, Yating Zeng, Yuqin Yi, Rong Liu, Yi Li, Xin Chen, Yan Cai, Shan Chen, Ping Ther Adv Respir Dis Original Research BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 report revised the combined assessment, merged the C and D groups into the E group, and revised the initial inhalation therapy recommendation. OBJECTIVES: This study aimed to analyze the future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease (COPD) in various groups based on the GOLD 2017 and GOLD 2023 reports. DESIGN: This is a multicenter and retrospective study. METHODS: Stable COPD patients from the database setup by 12 hospitals were enrolled. The patients were divided into Groups A, B, C, D, and E according to the GOLD 2017 and GOLD 2023 reports. Then, the patients were classified into long-acting muscarinic antagonist (LAMA), long-acting β2-agonist (LABA) + inhaled corticosteroid (ICS), LABA + LAMA, and LABA + LAMA + ICS subgroups. Data on exacerbation and death during 1 year of follow-up were collected. RESULTS: A total of 4623 patients were classified into Group A (15.0%), Group B (37.8%), Group C (7.3%), Group D (39.9%), and Group E (47.2%). The exacerbation, frequent exacerbation, and mortality showed no differences between different inhalation therapies in Groups A and C. Patients treated with LABA + LAMA or LABA + LAMA + ICS had a lower incidence of exacerbation and frequent exacerbation than patients treated with LAMA or LABA + ICS in Groups B, D, and E. The exacerbation, frequent exacerbation, and mortality showed no differences between different inhalation therapies after combining Groups A with C. CONCLUSION: Patients in Group A should be recommended to undergo mono-LAMA, while patients in Groups B and E should be recommended treatment with LABA + LAMA, which is consistent with the GOLD 2023 report. However, it is worth considering merging Groups A and C into a single group and recommending mono-LAMA as the initial inhalation therapy. SAGE Publications 2023-11-28 /pmc/articles/PMC10685753/ /pubmed/38018090 http://dx.doi.org/10.1177/17534666231213715 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc-nd/4.0/This article is distributed under the terms of the Creative Commons Attribution-NoDerivs 4.0 License (https://creativecommons.org/licenses/by-nc-nd/4.0/) which permits any use, reproduction and distribution of the work as published without adaptation or alteration, provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Song, Qing Cheng, Wei Liu, Cong Li, Xueshan Lin, Ling Peng, Yating Zeng, Yuqin Yi, Rong Liu, Yi Li, Xin Chen, Yan Cai, Shan Chen, Ping The future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease in various GOLD groups: a focus on the GOLD 2017 and GOLD 2023 reports |
title | The future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease in various GOLD groups: a focus on the GOLD 2017 and GOLD 2023 reports |
title_full | The future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease in various GOLD groups: a focus on the GOLD 2017 and GOLD 2023 reports |
title_fullStr | The future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease in various GOLD groups: a focus on the GOLD 2017 and GOLD 2023 reports |
title_full_unstemmed | The future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease in various GOLD groups: a focus on the GOLD 2017 and GOLD 2023 reports |
title_short | The future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease in various GOLD groups: a focus on the GOLD 2017 and GOLD 2023 reports |
title_sort | future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease in various gold groups: a focus on the gold 2017 and gold 2023 reports |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685753/ https://www.ncbi.nlm.nih.gov/pubmed/38018090 http://dx.doi.org/10.1177/17534666231213715 |
work_keys_str_mv | AT songqing thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT chengwei thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT liucong thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT lixueshan thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT linling thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT pengyating thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT zengyuqin thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT yirong thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT liuyi thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT lixin thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT chenyan thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT caishan thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT chenping thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT songqing futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT chengwei futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT liucong futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT lixueshan futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT linling futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT pengyating futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT zengyuqin futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT yirong futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT liuyi futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT lixin futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT chenyan futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT caishan futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports AT chenping futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports |